natgillin/translations-raw huggingface dataset:
Den primære fordel var på 27, 5% (95% konfidensinterval:
The primary benefit was a 27.5% (95% CI:
17 til 37%) reduktion af risiko for tid til første hospitalisering pga. hjertesvigt (13, 9% vs.
17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs.
18, 5%).
18.5%).
36 mortalitet og morbiditet var 21, 9% ved placebo vs.
Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs.
25, 4% i valsartan- gruppen) blev observeret for de patienter, der fik tredobbelt kombination af en ACE- hæmmer, en beta- blokker og valsartan.
25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.
I en undergruppe af patienter, der ikke fik en ACE- hæmmer (n=366), var morbiditetsfordelene størst.
In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest.
I denne undergruppe blev mortaliteten uanset årsag signifikant reduceret med valsartan sammenlignet med placebo med 33% (95% konfidensinterval: – 6% til 58%) (17, 3% valsartan vs.
In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by
27, 1% placebo) og den samlede mortalitets - og morbiditetsrisiko blev signifikant reduceret med 44% (24, 9% valsartan vs.
27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs.
42, 5% placebo).
42.5% placebo).
Hos patienter, der fik en ACE- hæmmer uden betablokker, var mortaliteten uanset årsag ensartet (p=NS) i valsartan - (21, 8%) og placebo - (22, 5%) gruppen.
In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups.
Den samlede mortalitets - og morbiditetsrisiko blev signifikant reduceret med 18, 3% (95% konfidensinterval:
Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI:
8% til 28%) med valsartan sammenlignet med placebo (31, 0% vs.
8% to 28%) with valsartan compared with placebo (31.0% vs.
36, 3%).
36.3%).
I den samlede Val- HeFT population viste patienter behandlet med valsartan signifikante forbedringer i NYHA- klasse og tegn og symptomer på hjertesvigt, inklusive dyspnø, træthed, ødem og rallen sammenlignet med placebo.
In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo.
Hypertension Når Diovan administreres til hypertensive patienter, sker der en reduktion af blodtrykket uden påvirkning af pulsen.
Hypertension Administration of Diovan to patients with hypertension results in reduction of blood pressure without affecting pulse rate.
Efter oral indtagelse af en enkelt dosis, sætter den antihypertensive effekt ind hos de fleste patienter i løbet af 2 timer, og den maksimale reduktion af blodtrykket opnås i løbet af 4- 6 timer.
In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours.
Pludselig seponering af Diovan har ikke resulteret i rebound- hypertension eller andre uønskede hændelser.
Abrupt withdrawal of Diovan has not been associated with rebound hypertension or other adverse clinical events.
Hos hypertensive patienter med type - diabetes og mikroalbuminuri har valsartan vist sig at reducere udskillelse af albumin via urinen.
In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin.
MARVAL (Micro Albuminuria Reduction with Valsartan) - undersøgelsen vurderede reduktionen i udskillelse af albumin via urinen (UAE) med valsartan (80 - 160 mg/ od) versus amlodipin (5- 10 mg/ od), hos 332 type diabetespatienter (gennemsnitsalder:
The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/ od) versus amlodipine (5-10 mg/ od), in 332 type 2 diabetic patients (mean age:
58 år; 265 mænd) med mikroalbuminuri (valsartan:
58 years; 265 men) with microalbuminuria (valsartan:
58 µg/ min; amlodipin:
58 µg/ min; amlodipine:
55, 4 µg/ min) og normalt eller højt blodtryk og med bevaret nyrefunktion (blodkreatinin < 120 µmol/ l).
55.4 µg/ min), normal or high blood pressure and with preserved renal function (blood creatinine < 120 µmol/ l).
Efter 24 uger var UAE reduceret (p < 0, 001) med 42% (– 24, 2 µg/ min; 95% konfidensinterval: – 40, 4 til – 19, 1) med valsartan og cirka 3% (– 1. 7 µg/ min; 95% konfidensinterval: – 5, 6 til 14, 9) med amlodipin trods ensartet reduktion af blodtryksværdierne i begge grupper.
At 24 weeks, UAE was reduced (p < 0.001) by 42% (– 24.2 µg/ min; 95% CI: – 40.4 to – 19.1) with valsartan and approximately 3% (– 1.7 µg/ min; 95% CI: – 5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.
DROP (Diovan Reduction of Proteinuria) - undersøgelsen undersøgte yderligere effektiviteten af valsartan mht. reduktion af UAE hos 391 hypertensive patienter (BT=150/ 88 mmHg) med type - diabetes, albuminuri (gennemsnit=102 µg/ min; 20- 700 µg/ min) og bevaret nyrefunktion (gennemsnitlig serumkreatinin = 80 µmol/ l).
The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/ 88 mmHg) with type 2 diabetes, albuminuria (mean=102 µg/ min; 20-700 µg/ min) and preserved renal function (mean serum creatinine = 80 µmol/ l).
Patienterne blev randomiseret til en af 3 valsartandoser (160, 320 og 640 mg/ od) og behandledes i 30 uger.
Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/ od) and treated for 30 weeks.
Formålet med undersøgelsen var at bestemme den optimale valsartandosis til reduktion af UAE hos hypertensive patienter med type - diabetes.
The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes.
Efter 30 uger var den procentmæssige ændring af UAE signifikant reduceret med 36% i forhold til baseline med valsartan 160 mg (95% konfidensinterval:
At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI:
22 til 47%) og med 44% med valsartan 320 mg (95% konfidensinterval:
22 to 47%), and by 44% with valsartan 320 mg (95%CI:
31 til 54%).
31 to 54%).
Heraf udledtes, at 160- 320 mg valsartan gav klinisk relevante reduktioner af UAE hos hypertensive patienter med type - diabetes.
It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.
Patienterne blev randomiseret inden for 12 timer til 10 dage efter indtræden af symptomer på myokardieinfarkt til valsartan, captopril eller en
Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both.
37 kombination af begge Den gennemsnitlige behandlingsvarighed var 2 år.
The mean treatment duration was two years.
Der var ingen forskel mellem valsartan og captopril med hensyn til totalmortalitet, baseret på alder, køn, race, baseline- behandlinger eller tilgrundliggende sygdom.
There was no difference between valsartan and captopril in all-cause mortality based on age, gender,
Resultater, der taler til fordel for placebo (samlet mortalitet og morbiditet var 21, 9% ved placebo vs.
Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs.
I denne undergruppe blev mortaliteten uanset årsag signifikant reduceret med valsartan sammenlignet med placebo med 33% (95% konfidensinterval: – 6% til 58%) (17, 3% valsartan vs.
In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: – 6% to 58%) (17.3% valsartan vs.
38 Hypertension Når Diovan administreres til hypertensive patienter, sker der en reduktion af blodtrykket uden påvirkning af pulsen.
Hypertension Administration of Diovan to patients with hypertension results in reduction of blood pressure without affecting pulse rate.
Pludselig seponering af Diovan har ikke resulteret i rebound- hypertension eller andre uønskede hændelser.
40 Abrupt withdrawal of Diovan has not been associated with rebound hypertension or other adverse clinical events.
Efter oral administration af valsartan alene nås maksimale plasmakoncentrationer af valsartan efter 2 – 4 timer.
Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2– 4 hours.
Føde reducerer eksponeringen (målt ved AUC) for valsartan med cirka 40%, og den maksimale plasmakoncentration (C max) med cirka 50%, selv om valsartankoncentrationen i plasma fra cirka 8 timer efter doseringen er ens for gruppen med føde og en fastende gruppe.
Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C max) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups.
Steady- state fordelingsvolumen af valsartan efter intravenøs administration er cirka 17 liter, hvilket tyder på, at valsartan ikke fordeles i omfattende grad i væv.
The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively.
Valsartan er i høj grad bundet til serumproteiner (94– 97%), hovedsageligt serumalbumin.
Valsartan is highly bound to serum proteins (94– 97%), mainly serum albumin.
Valsartan biotransformeres ikke i stort omfang, idet kun cirka 20% af dosen genfindes som metabolitter.
Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites.
En hydroxymetabolit er blevet identificeret i plasma i lave koncentrationer (mindre end 10% af valsartans AUC).
A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC).
Valsartan udviser tokompartment halveringskinetik (t ½α < 1 time og t ½ß omkring 9 timer).
Valsartan shows multiexponential decay kinetics (t ½α < 1 h and t ½ß about 9 h).
Valsartan udskilles primært ved galdeudskillelse i fæces (cirka 83% af dosis) og renalt i urin (cirka 13% af dosis), hovedsageligt som uomdannet stof.
Valsartan is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug.
39 l/ t, og den renale clearance er 0, 62 l/ t (cirka 30% af den totale clearance).
Following intravenous administration, plasma clearance of valsartan is about 2 l/ h and its renal clearance is 0.62 l/ h (about 30% of total clearance).
Valsartans gennemsnitlige tid til maksimal koncentration og udskillelses- halveringstid hos patienter med hjertesvigt svarer til det, der er observeret hos raske frivillige.
The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers.
AUC - og cm ax værdier for valsartan er omtrent proportionale med stigende dosis over det kliniske dosisspænd (40- 160 mg, 2 gange daglig).
AUC and C max values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day).
Den gennemsnitlige akkumuleringsfaktor er ca.
The average accumulation factor is about 1.7.
4, 5 l/ t efter oral administration.
The apparent clearance of valsartan following oral administration is approximately 4.5 l/ h.
Patienter med hjertesvigt:
41 In Heart failure patients:
Specielle patientpopulationer Ældre Hos nogle ældre patienter blev der observeret en noget højere plasmakoncentration af valsartan end hos yngre patienter, men det er ikke vist at have nogen klinisk signifikans.
Special populations Elderly A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.
Nedsat nyrefunktion Som forventet for et stof med en nyre- clearance på kun 30% af total plasmaclearance, er der ikke observeret nogen korrelation mellem nyrefunktion og systemisk eksponering af valsartan.
Impaired renal function As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.
Dosisjustering er derfor ikke påkrævet for patienter med nedsat nyrefunktion (kreatinin- clearance > 10 ml/ min).
Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance > 10 ml/ min).
4. 2 og 4. 4).
There is currently no experience on the safe use in patients with a creatinine clearance < 10 ml/ min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4).
Nedsat leverfunktion Cirka 70% af den absorberede dosis udskilles i galden, hovedsageligt i uændret form.
Hepatic impairment Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form.
Der blev dog ikke observeret nogen korrelation mellem valsartan- koncentrationer i blodet og graden af leverinsufficiens.
However, no correlation was observed between plasma valsartan concentration versus degree of hepatic dysfunction.
4. 2, 4. 3 og 4. 4).
Diovan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).
4. 6).
In rats, maternally toxic doses (600 mg/ kg/ day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6).
Disse doser hos rotter (600 mg/ kg/ dag) er cirka 18 gange højere end den anbefalede humane maksimumdosis, udregnet ifølge mg/ m2 (beregningerne går ud fra en oral dosis på 320 mg/ dag til en patient, der vejer 60 kg).
These doses in rats (600 mg/ kg/ day) are approximately 18 times the maximum recommended human dose on a mg/ m2 basis (calculations assume an oral dose of 320 mg/ day and a 60-kg patient).
I prækliniske sikkerhedsundersøgelser på rotter forårsagede høje doser valsartan (200- 600 mg/ kg legemsvægt) reduktion af blodtal (erytrocytter, hæmoglobin og hæmatokritværdi) og tegn på ændringer i den renale hæmodynamik (lettere forhøjet plasma- urinstof, samt renal tubulær hyperplasi og basofili hos hanner).
In non-clinical safety studies, high doses of valsartan (200 to 600 mg/ kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males).
Hos silkeaber, som fik lignende doser, sås det samme, skønt mere alvorlige ændringer, især i nyrerne, hvor ændringerne udviklede sig til nefropati, som omfattede forhøjet urinstof og serum- kreatinin.
In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.
40 Hypertrofi af de renale juxtaglomerulære celler synes ikke at have relevans for mennesker, som får terapeutiske doser valsartan.
For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
[Udfyldes nationalt]
42 [To be completed nationally]
41 ETIKETTERING
43 LABELLING
42 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
44 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Diovan og tilhørende navne (se bilag I) 40 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 40 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 80 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 80 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 160 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 160 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 320 mg filmovertrukne tabletter Valsartan
Diovan and associated names (see Annex I) 40 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 40 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 80 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 80 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 160 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 160 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 320 mg film-coated tablets Valsartan
43 7.
45 7.
44 MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT ELLER BLISTERSTRIPS
46 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Diovan og tilhørende navne (se bilag I) 40 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 40 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 80 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 80 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 160 mg filmovertrukne tabletter Valsartan Diovan og tilhørende navne (se bilag I) 160 mg kapsler, hårde Valsartan Diovan og tilhørende navne (se bilag I) 320 mg filmovertrukne tabletter Valsartan [Se Bilag I – Udfyldes nationalt]
Diovan and associated names (see Annex I) 40 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 40 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 80 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 80 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 160 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 160 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 320 mg film-coated tablets Valsartan [See Annex I - To be completed nationally]
45 INDLÆGSSEDDEL
47 PACKAGE LEAFLET
46 INDLÆGSSEDDEL:
48 PACKAGE LEAFLET:
Diovan og tilhørende navne (se bilag I) 40 mg filmovertrukne tabletter Diovan og tilhørende navne (se bilag I) 40 mg kapsler, hårde Diovan og tilhørende navne (se bilag I) 80 mg filmovertrukne tabletter Diovan og tilhørende navne (se bilag I) 80 mg kapsler, hårde Diovan og tilhørende navne (se bilag I) 160 mg filmovertrukne tabletter Diovan og tilhørende navne (se bilag I) 160 mg kapsler, hårde Diovan og tilhørende navne (se bilag I) 320 mg filmovertrukne tabletter [Se Bilag I – Udfyldes nationalt] Valsartan
Diovan and associated names (see Annex I) 40 mg film-coated tablets Diovan and associated names (see Annex I) 40 mg capsules, hard Diovan and associated names (see Annex I) 80 mg film-coated tablets Diovan and associated names (see Annex I) 80 mg capsules, hard Diovan and associated names (see Annex I) 160 mg film-coated tablets Diovan and associated names (see Annex I) 160 mg capsules, hard Diovan and associated names (see Annex I) 320 mg film-coated tablets [See Annex I -To be completed nationally] Valsartan
Læs denne indlægsseddel grundigt inden du begynder at tage medicinen.  Gem indlægssedlen.
Read all of this leaflet carefully before you start taking this medicine.  Keep this leaflet.
Du kan få brug for at læse den igen.  Spørg lægen eller på apoteket, hvis der er mere, du vil vide.  Lægen har ordineret Diovan til dig personligt.
You may need to read it again.  If you have any further questions, ask your doctor or pharmacist.  This medicine has been prescribed for you.
Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har.  Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt her.
It may harm them, even if their symptoms are the same as yours.  If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Virkning og anvendelse 2.
What Diovan is and what it is used for 2.
Det skal du vide, før du begynder at tage Diovan 3.
Before you take Diovan 3.
Sådan skal du tage Diovan 4.
How to take Diovan 4.
Opbevaring 6.
How to store Diovan 6.
VIRKNING OG ANVENDELSE
WHAT DIOVAN IS AND WHAT IT IS USED FOR
Diovan tilhører en gruppe medicin, der kaldes angiotensin- II- hæmmere, der hjælper med at sænke forhøjet blodtryk.
Diovan belongs to a class of medicines known as angiotensin II receptor antagonist, which help to control high blood pressure.
Angiotensin- II er et stof, som findes i kroppen og får blodkarrene til at trække sig sammen, sådan at blodtrykket stiger.
Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase.
Diovan hæmmer virkningen af angiotensin- II.
Diovan works by blocking the effect of angiotensin II.
Diovan 40 mg filmovertrukne tabletter kan bruges til to forskellige tilstande:  Behandling af patienter, som for nylig har haft et hjerteanfald (myokardieinfarkt). “ Nylig ” betyder her mellem 12 timer og 10 dage.  Behandling af symptomatisk hjertesvigt.
Diovan 40 mg film-coated tablets can be used for two different conditions:  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
Diovan bruges, når en gruppe lægemidler kaldet angiotensinkonverterende enzym (ACE) - hæmmere (et lægemiddel til behandling af hjertesvigt) ikke kan bruges.
Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used.
Diovan kan dog bruges som supplement til ACE- hæmmere, når betablokkere (et andet lægemiddel til behandling af hjertesvigt) ikke kan bruges.
Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up.
Hjertesvigt er forbundet med åndenød og hævede fødder og ben på grund af væskeansamlinger.
It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.
Diovan 40 mg hårde kapsler kan bruges til to forskellige tilstande:  Behandling af patienter, som for nylig har haft et hjerteanfald (myokardieinfarkt). “ Nylig ” betyder her mellem 12 timer og 10 dage.  Behandling af symptomatisk hjertesvigt.
Diovan 40 mg capsules, hard can be used for two different conditions:  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
Diovan bruges, når en gruppe lægemidler kaldet angiotensinkonverterende enzym (ACE) - hæmmere (et lægemiddel til behandling af hjertesvigt) ikke kan bruges.
Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure)
47 Diovan 80 mg filmovertrukne tabletter kan bruges til tre forskellige tilstande:  Behandling af forhøjet blodtryk.
Diovan 80 mg film-coated tablets can be used for three different conditions:  to treat high blood pressure.
Ved at sænke blodtrykket til et normalt niveau nedsættes risikoen for at få disse lidelser.  Behandling af patienter, som for nylig har haft et hjerteanfald (myokardieinfarkt). “ Nylig ” betyder her mellem 12 timer og 10 dage.  Behandling af symptomatisk hjertesvigt.
Lowering your blood pressure to normal reduces the risk of developing these disorders.  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
Diovan 80 mg hårde kapsler kan bruges til tre forskellige tilstande:  Behandling af forhøjet blodtryk.
Diovan 80 mg capsules, hard can be used for three different conditions:  to treat high blood pressure.